Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Petros PharmaceuticalsPTPI Earnings Yield (Joel Greenblatt) % is 102.04% as of Mar. 2026. Among 1,010 Drug Manufacturers companies, Petros Pharmaceuticals ranks worse than 99009.8% on this metric.
Petros Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was $-4.12 Mil.
Petros Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.21 Mil. Petros Pharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 102.04%.
The historical rank and industry rank for Petros Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
PTPI'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -60091.43 Med: -105.96 Max: 4231.79
Current: 277.78
During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Petros Pharmaceuticals was 4231.79%. The lowest was -60091.43%. And the median was -105.96%.
PTPI's Earnings Yield (Joel Greenblatt) % is not ranked
in the Drug Manufacturers industry.
Industry Median: 3.375
vs PTPI: 277.78
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Petros Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Petros Pharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms
Petros Pharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Petros Pharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Petros Pharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Petros Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.21 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 102.04% mean?
Petros Pharmaceuticals (PTPI) has a Earnings Yield (Joel Greenblatt) % of 102.04% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Petros Pharmaceuticals and its competitors. According to the industry distribution chart, Petros Pharmaceuticals ranks #999999 out of 1010 companies in the Drug Manufacturers industry.
Is Petros Pharmaceuticals' Earnings Yield (Joel Greenblatt) % too high?
Petros Pharmaceuticals' current Earnings Yield (Joel Greenblatt) % is 102.04%. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.38. Petros Pharmaceuticals' value of 102.04% is 2923.4% above this industry median. Based on the distribution chart, Petros Pharmaceuticals ranks #999999 out of 1010 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Petros Pharmaceuticals' Earnings Yield (Joel Greenblatt) % compare to KOAN and KAYS?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #999999 out of 1010 companies for Earnings Yield (Joel Greenblatt) %. This places Petros Pharmaceuticals in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.38. Petros Pharmaceuticals' value of 102.04% is 2923.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.38, based on 1,010 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Petros Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % of 102.04% is 2923.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % is 102.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Earnings Yield (Joel Greenblatt) % of 102.04%. The current Earnings Yield (Joel Greenblatt) % is 102.04% and 2923.4% above the Drug Manufacturers industry median of 3.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Earnings Yield (Joel Greenblatt) % is 102.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 
